#USA #Santa Clara #Persistent Systems #NVIDIA #GenMoIVS

Persistent Systems Revolutionizes Drug Discovery with AI

Persistent Systems, a global leader in digital engineering and enterprise modernization, has announced its pioneering collaboration with NVIDIA to advance drug discovery efforts in the life sciences sector. With the powerful capabilities of generative AI and advanced analytics, this initiative stands to significantly improve research outcomes and streamline the development process for new therapies.

The Challenge in Healthcare

In the fast-paced and heavily regulated healthcare environment, organizations are pressured to innovate while managing vast amounts of data. Traditional research and development methods often fall short, leading to extended timelines and high costs that hinder the discovery of new therapies. To address these challenges, Persistent Systems is harnessing the robust NVIDIA AI platform to transition from slow, manual processes to agile, AI-driven methodologies.

Collaborating with NVIDIA

By leveraging NVIDIA's comprehensive AI suite, including the BioNeMo framework, Persistent Systems aims to enable computational drug discovery with greater efficiency and accuracy. This partnership will facilitate the simulation of complex molecular interactions, allowing researchers to validate hypotheses and streamline experimentation processes without the immediate need for wet lab environments.

Introducing GenMoIVS

The highlight of this collaboration is the introduction of the Generative Molecules and Virtual Screening solution, or GenMoIVS, which integrates seamlessly with NVIDIA's technology. This innovative tool utilizes AI to simulate molecular properties, enabling researchers to foresee chemical interactions and biological responses before physical experiments take place. By doing so, it minimizes risks associated with early-stage discoveries and accelerates the clinical development pipeline.

GenMoIVS offers real-time decision-making capabilities during the virtual screening process, prioritizing potential drug candidates efficiently. This AI-assisted methodology heralds a new era in the drug discovery landscape, moving from traditional timelines of months to a matter of days, thus empowering biopharma companies to conduct experiments that are both scientifically rigorous and compliant with regulatory standards.

Enhancing Engineering Capabilities

Persistent Systems plans to bolster its AI and Large Language Model (LLM) capabilities further by tapping into NVIDIA’s training resources and certifications. This investment will enhance Persistent’s capacity to deliver sophisticated AI and data platforms to its clients, ensuring they remain at the forefront of innovation.

As Ganesh Nathella, Executive Vice President and General Manager of the Health and Life Sciences Business at Persistent, articulates: “The healthcare sector must accelerate the discovery of therapies, and our solution allows biopharma companies to leverage generative molecules and virtual screenings in production—transitioning from lengthy experiments to AI-driven discovery.”

John Fanelli, Vice President of Enterprise Software at NVIDIA, also emphasizes: “With Persistent utilizing the NVIDIA AI platform, biopharmaceutical companies can implement production-grade systems for molecular simulations and virtual screenings, thereby meeting the pressing demand for new therapies globally.”

A Commitment to Sustainability

Persistent Systems is not only making strides in technological advancements; the company remains committed to sustainable practices and corporate social responsibility. It has achieved carbon neutrality and is actively engaged in promoting diversity and inclusion, as recognized by various organizations.

This innovation in drug discovery through the use of AI represents a tremendous leap forward for Persistent Systems and its partners in the life sciences. By combining cutting-edge technology with an unwavering commitment to innovation, Persistent is set to redefine the boundaries of drug discovery, making significant contributions to the future of healthcare.

For more information, visit Persistent Systems.